10-Q: Evolent Health Navigates Revenue Shifts, Debt Refinancing in Q3 2025

Evolent Health reported a 22.8% revenue decline in Q3 2025 due to contractual changes, but improved operating income, while undertaking significant debt refinancing and asset disposal.

Summary

• Revenue decreased by $141.9 million (22.8%) to $479.5 million for the three months ended September 30, 2025, primarily due to contractual updates in the Performance Suite, including a customer transition and scope narrowing.
• Cost of revenue decreased by $160.9 million (29.8%) to $379.8 million for the three months ended September 30, 2025, improving as a percentage of revenue from 87.0% to 79.2%.
• Operating income improved significantly to $0.886 million in Q3 2025 from a loss of $16.268 million in Q3 2024.
• Net loss attributable to common shareholders improved to $(26.930) million in Q3 2025 from $(31.231) million in Q3 2024.
• For the nine months ended September 30, 2025, net loss attributable to common shareholders increased to $(150.270) million from $(62.839) million in the prior year, largely due to a $52.5 million loss on option exercise and $15.0 million in refinancing fees.
• The company agreed to sell Evolent Care Partners Holding Company, Inc. for $100.0 million, plus a contingent payment of up to $13.0 million, expected to close in Q4 2025.
• Completed significant debt refinancing, including issuing $166.8 million in 2031 Convertible Senior Notes and repurchasing $167.4 million of 2025 Convertible Senior Notes.
• Exchanged Series A Preferred Stock for a new $175.0 million second lien term loan facility.

Sentiment

Score: 4

Explanation: While Q3 operating income showed improvement and cost of revenue as a percentage of revenue decreased, the significant year-to-date net loss increase, driven by non-operating items like the loss on option exercise and refinancing fees, and the substantial revenue decline, indicate underlying challenges. The increased long-term debt and ongoing industry headwinds (rising medical costs, regulatory uncertainty) contribute to a cautious outlook, despite strategic moves like asset disposal and debt refinancing.

Positives

• Operating income improved to $0.886 million in Q3 2025 from a loss of $16.268 million in Q3 2024, representing a 105.4% improvement.
• Net loss attributable to common shareholders improved in Q3 2025 to $(26.930) million from $(31.231) million in Q3 2024.
• Cost of revenue as a percentage of total revenue decreased from 87.0% in Q3 2024 to 79.2% in Q3 2025, indicating a shift towards higher-margin product types.
• Recorded a $1.2 million gain on lease termination for the three months ended September 30, 2025.
• Successfully refinanced debt by issuing new 2031 Convertible Senior Notes and repurchasing 2025 Convertible Senior Notes, resulting in a $0.4 million gain on extinguishment of short-term debt.
• Cash and cash equivalents increased to $116.650 million as of September 30, 2025, from $104.203 million at December 31, 2024.

Negatives

• Total revenue decreased by $141.9 million (22.8%) for Q3 2025 and $500.7 million (26.2%) for the nine months ended September 30, 2025, primarily due to contractual updates and membership reductions.
• Net loss attributable to common shareholders significantly increased for the nine months ended September 30, 2025, to $(150.270) million from $(62.839) million in the prior year.
• Incurred a $52.5 million loss on option exercise related to the purchase of a portion of an equity method investment, which will have no continuing operations.
• Recorded a $15.0 million charge for extinguishment of Series A Preferred Stock and other refinancing fees for the nine months ended September 30, 2025.
• Selling, general and administrative expenses increased by 15.7% in Q3 2025 and 7.4% for the nine months ended September 30, 2025, and increased as a percentage of revenue.
• Long-term debt, net, significantly increased to $1,054.822 million as of September 30, 2025, from $490.520 million at December 31, 2024.
• Medical claims costs in the Performance Suite continued to grow faster than historical averages in 2025, impacting financial results.
• A $0.7 million loss on lease termination was recorded for the nine months ended September 30, 2025.

Risks

• A significant portion of revenue is derived from largest partners; the loss, termination, or renegotiation of contracts with any significant partner or multiple partners could have a material adverse effect.
• The increasing number of risk-sharing arrangements entered into with partners introduces greater financial exposure.
• The growth and success of partners and certain revenues are difficult to predict and are subject to factors outside of the company's control, including governmental funding reductions and other policy changes (e.g., Medicaid redeterminations, Medicare Advantage changes).
• Inability to accurately predict exposure under performance-based contracts.
• Risks related to completed and future acquisitions, investments, alliances, and joint ventures, which could divert management resources, result in unanticipated costs, or dilute stockholders.
• The evolution of the healthcare regulatory and political framework, including the impact of the One Big Beautiful Bill Act (OBBBA) on Medicaid, Medicare, and ACA Health Exchanges, could result in reductions in members covered by partners' health care plans.
• Liabilities and reputational risks related to the ability to safeguard the security and privacy of confidential data.
• Risks associated with the use of artificial intelligence (AI) and machine learning models.
• Exposure to interest rate risk under Credit Agreements, with a 1% increase in SOFR potentially leading to $4.53 million in additional annual interest expense.
• Significant debt and other obligations could adversely affect financial health, limit the ability to obtain future financing, and restrict business flexibility.
• Potential inability to raise funds necessary to settle conversions of notes in cash, repurchase notes for cash upon a fundamental change, or pay redemption prices.
• A Civil Investigative Demand (CID) was received from the Department of Justice regarding a False Claims Act investigation concerning unsupported diagnosis codes in Medicare Advantage beneficiaries by a former customer, with an unknown scope, duration, or potential loss.
• Concentration of credit risk related to cash and cash equivalents (deposits exceeding FDIC limits) and accounts receivable (substantial portion from a small number of partners).
• The impact of increasing inflationary pressures and rising consumer costs on the business could negatively impact margins and profitability in future periods.

Future Outlook

The company anticipates continued growth in the cost of treatment for cancer and cardiovascular patients, expecting this to be offset by contractual protections and clinical interventions. It is unable to predict the future impact of broader industry dynamics, such as elevated medical expenses and the expiration of premium tax credits on ACA Health Exchanges, or the effects of the OBBBA on its business, which could be material. The company believes its current cash and cash equivalents will be sufficient to meet working capital and capital expenditure requirements for at least the next twelve months.

Management Comments

• We believe adherence to the best evidence supports better outcomes for patients, a better experience for physicians, and lower costs for the healthcare system overall.
• We believe Evolent can bring an integrated approach to a patient's condition across multiple specialties, using technology to recommend our evidence-based clinical pathways in a way that provides rapid feedback to the provider, seeks to remove barriers to care, and aligns financial incentives with the best evidence.
• We anticipate continued growth in the cost of treatment for cancer and cardiovascular patients over time, which we expect to be offset by contractual protections within our Performance Suite and the impact of our clinical interventions.
• We are unable to predict how these broader dynamics will impact our business and results of operations in the future, but they could continue to impact our financial condition and results of operations and such future impacts could be material.
• The Company continues to evaluate the expected impact of the OBBBA on its business and financial statements, but changes resulting from the OBBBA could have a material adverse effect on our business, results of operations, financial condition or cash flows.
• We believe our current cash and cash equivalents will be sufficient to meet our working capital and capital expenditure requirements for at least the next twelve months as of the date the financial statements were issued.

Industry Context

The healthcare industry is experiencing significant shifts, including rising medical claims costs, particularly in specialty care, which Evolent Health aims to manage through its value-based care solutions. The company's performance is also influenced by governmental policy changes, such as Medicaid redeterminations and the recently enacted One Big Beautiful Bill Act (OBBBA), which could impact health plan membership and federal support for healthcare programs. Industry-wide expectations of lower ACA Health Exchange membership in 2026 due to elevated medical expenses and expiring premium tax credits also pose a challenge. Evolent Health's strategy of focusing on integrated specialty care management aligns with the broader trend of moving towards value-based care models to control escalating costs for complex conditions.

Comparison to Industry Standards

• Medical claims costs in the Performance Suite grew at a significantly faster rate than historical norms during 2024 and the first three quarters of 2025, which is believed to be an industry-wide trend and not specific to Evolent.
• Commentary from other market participants suggests that the elevated medical claims costs are an industry-wide phenomenon.
• Industry expectations point to lower ACA Health Exchange membership in 2026 due to elevated medical expenses and expiring premium tax credits, indicating a broader market challenge.

Corporate Governance

Legal Proceedings

• A Civil Investigative Demand (CID) was received from the Department of Justice on August 12, 2025, pursuant to a False Claims Act investigation concerning allegations that a former customer and/or certain other parties may have submitted unsupported diagnosis codes in connection with Medicare Advantage beneficiaries. The company is cooperating but cannot predict the outcome or estimate potential losses.
• A shareholder derivative action filed on June 8, 2021, was dismissed without prejudice by the Delaware Chancery Court on January 5, 2023.
• A shareholder demand letter from April 6, 2023, requesting investigation and litigation for breach of fiduciary duty against certain individuals, was refused by the Board on February 15, 2024.

Related Party Transactions

• The company had an economic relationship with an entity whose President and Chief Executive Officer was a Board member until February 2024, which accounted for the majority of related party revenue and cost of revenue for the three months ended March 31, 2024.
• The company holds economic interests in several equity method investees, ranging between 4% and 25% as of September 30, 2025.
• Services agreements with these equity method investees generated $3.9 million in revenue for the three months ended September 30, 2025, and $7.969 million for the nine months ended September 30, 2025.
• Related party accounts receivable, net, totaled $6.124 million as of September 30, 2025.
• Related party accounts payable totaled $0.798 million as of September 30, 2025.

Stakeholder Impact

• Shareholders face potential dilution from future equity raises, impact of increased debt on financial health, volatility of Class A common stock price, and potential adverse effects on diluted earnings per share due to convertible debt accounting changes.
• Customers/Partners are affected by contractual updates and scope narrowing, which have led to revenue reductions but also lower claims costs. Medicaid redeterminations and changes in Medicare Advantage operations by clients could reduce membership and impact revenue.
• Employees may experience changes due to ongoing operational effectiveness and efficiency assessments, including past repositioning initiatives that resulted in severance costs.
• Creditors are impacted by the company's increased long-term debt and restrictive covenants in credit agreements, which could limit financial flexibility and the ability to service debt.

Next Steps

• Close the sale of Evolent Care Partners Holding Company, Inc. in Q4 2025.
• Continue to monitor for changes in facts or circumstances that may indicate potential goodwill impairment triggers.
• Evaluate the expected impact of the One Big Beautiful Bill Act (OBBBA) on the business and financial statements.
• Assess the impact of new FASB ASUs (2024-03, 2024-04, 2025-03, 2025-04, 2025-06) on consolidated financial statements and disclosures.
• Cooperate with the Department of Justice in the False Claims Act investigation.
• Manage debt service obligations and potentially seek additional financing for future growth or acquisitions.

Key Dates

Recommendation

Evolent Health is undergoing significant strategic and financial restructuring, including a major asset disposal and debt refinancing. While the company showed improved operating income in Q3 2025 and better cost of revenue margins, the substantial year-to-date net loss, driven by non-operating charges like the loss on an equity investment and refinancing fees, raises concerns. The revenue decline, coupled with industry-wide challenges such as rising medical costs and regulatory uncertainty (OBBBA, Medicaid redeterminations), creates a mixed outlook. The ongoing DOJ investigation adds an element of unpredictable risk. Given these factors, a 'hold' recommendation is appropriate as the company navigates these transitions and uncertainties, with potential for long-term value if strategic shifts prove successful, but also significant near-term headwinds and risks.

Keywords

Healthcare Technology, Value-Based Care, Specialty Care Management, Health Plans, Risk-Sharing, SEC Filing, 10-Q, Financial Results, Debt Refinancing, Asset Disposal, Convertible Notes, Medicare Advantage, Medicaid, ACA Health Exchanges, Artificial Intelligence, Corporate Governance, Evolent Health